Compare Medpace Holdings Inc (MEDP) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.63 (market cap $94.46M). The key difference: Medpace Holdings Inc is far larger — about 178.1× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days on average.
| MEDP | MSTZ | |
|---|---|---|
Market Cap | $16.82B | $94.46M |
Volume | 223,093 | 104,717,733 |
Sector | Health | Leveraged / Inverse |
52-Week High | $630.19 | $27.92 |
52-Week Low | $393.42 | $2.29 |
Typical Hold Time | 14 Days | 8 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
MSTZ trades at $2.58, down 3.01% with bearish technical signals from moving averages. The stock shows mixed momentum with neutral oscillators but negative moving average alignment. Key support sits at $2 with resistance at $3. Recent ETF coverage highlights the stock's inclusion in leveraged/inverse ETF discussions, though specific company fundamentals remain limited in available data.
Outlook remains cautious given technical weakness and limited fundamental visibility. The primary opportunity lies in potential technical rebounds from support levels, while risks include continued bearish momentum and lack of clear fundamental catalysts. Investors should await clearer financial metrics and earnings guidance for directional conviction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
